Comparison of efficacy of haloperidol and olanzapine in the treatment of delirium

Rajan Jain, Priti Arun, Ajeet Sidana, Atul Sachdev, Rajan Jain, Priti Arun, Ajeet Sidana, Atul Sachdev

Abstract

Objective: Till date, typical antipsychotic haloperidol is the treatment of choice for delirium. But, due to higher side effects with haloperidol, newer atypical antipsychotics (e.g., olanzapine) are increasingly being used in the treatment of delirious patients. The aim of the current research was to study the efficacy and tolerability of haloperidol and olanzapine in the treatment of delirium.

Materials and methods: This was an open-label, randomized controlled study carried out in a tertiary care hospital at Chandigarh, India. A total of 100 patients admitted in medicine, surgery, and orthopedic wards and diagnosed as having delirium on Confusion Assessment Method scale were included in the study. Patients were given either haloperidol (1-4 mg/day either orally or by nasogastric tube) or olanzapine (2.5-10 mg/day either orally or by nasogastric tube). Severity of delirium and pattern of symptom improvement were assessed by Memorial Delirium Assessment Scale (MDAS). Extrapyramidal side effects were assessed by Simpson-Angus Scale.

Results: There was an improvement in delirium severity in both groups with treatment. Mean daily dose of haloperidol and olanzapine used per patient was 2.10 and 5.49 mg, respectively, and the mean duration of treatment in olanzapine group and haloperidol group was 3.57 days and 3.37 days, respectively. There was no significant difference in the mean duration of treatment in both groups. At the end of study period, the MDAS scores in olanzapine and haloperidol groups were 8.43 and 8.00, respectively, and the difference was not significant statistically with P = 0.765. Five patients experienced drug-related mild side effects.

Conclusion: Low-dose haloperidol and olanzapine were equally efficacious and well tolerated in delirium.

Keywords: Delirium; efficacy; haloperidol; olanzapine; tolerability.

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Flow Chart

References

    1. Trzepacz PT, Meagher DJ. Delirium. In: Levenson JL, editor. Textbook of Psychosomatic Medicine. Washington, DC: American Psychiatric Association; 2005.
    1. Thomas RI, Cameron DJ, Fahs MC. A prospective study of delirium and prolonged hospital stay. Exploratory study. Arch Gen Psychiatry. 1988;45:937–40.
    1. Inouye SK, Rushing JT, Foreman MD, Palmer RM, Pompei P. Does delirium contribute to poor hospital outcomes? A three-site epidemiologic study. J Gen Intern Med. 1998;13:234–42.
    1. Lacasse H, Perreault MM, Williamson DR. Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients. Ann Pharmacother. 2006;40:1966–73.
    1. Conn DK, Lieff S. Diagnosing and managing delirium in the elderly. Can Fam Physician. 2001;47:101–8.
    1. Breitbart W, Marotta R, Platt MM, Weisman H, Derevenco M, Grau C, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry. 1996;153:231–7.
    1. Tune L. The role of antipsychotics in treating delirium. Curr Psychiatry Rep. 2002;4:209–12.
    1. Han CS, Kim YK. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics. 2004;45:297–301.
    1. Parellada E, Baeza I, de Pablo J, Martínez G. Risperidone in the treatment of patients with delirium. J Clin Psychiatry. 2004;65:348–53.
    1. Breitbart W, Tremblay A, Gibson C. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics. 2002;43:175–82.
    1. Grover S, Kumar V, Chakrabarti S. Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. J Psychosom Res. 2011;71:277–81.
    1. Hu H, Deng W, Yang H, Liu Y. Olanzapine and haloperidol for senile delirium: A randomized controlled observation. Chin J Clin Rehabil. 2006;10:188–90.
    1. Kim KS, Pae CU, Chae JH, Bahk WM, Jun T. An open pilot trial of olanzapine for delirium in the Korean population. Psychiatry Clin Neurosci. 2001;55:515–9.
    1. Sipahimalani A, Masand PS. Olanzapine in the treatment of delirium. Psychosomatics. 1998;39:422–30.
    1. Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs. Haloperidol: Treating delirium in a critical care setting. Intensive Care Med. 2004;30:444–9.
    1. Yoon HJ, Park KM, Choi WJ, Choi SH, Park JY, Kim JJ, et al. Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. BMC Psychiatry. 2013;13:240.
    1. Kim KY, Bader GM, Kotlyar V, Gropper D. Treatment of delirium in older adults with quetiapine. J Geriatr Psychiatry Neurol. 2003;16:29–31.
    1. Pae CU, Lee SJ, Lee CU, Lee C, Paik IH. A pilot trial of quetiapine for the treatment of patients with delirium. Hum Psychopharmacol. 2004;19:125–7.
    1. Hu H, Deng W, Yang H. A prospective random control study comparison of olanzapine and haloperidol in senile delirium. Chongging Med J. 2004;8:1234–7.
    1. Kim SW, Yoo JA, Lee SY, Kim SY, Bae KY, Yang SJ, et al. Risperidone versus olanzapine for the treatment of delirium. Hum Psychopharmacol. 2010;25:298–302.
    1. Larsen KA, Kelly SE, Stern TA, Bode RH, Jr, Price LL, Hunter DJ, et al. Administration of olanzapine to prevent postoperative delirium in elderly joint-replacement patients: A randomized, controlled trial. Psychosomatics. 2010;51:409–18.
    1. Kishi T, Hirota T, Matsunaga S, Iwata N. Antipsychotic medications for the treatment of delirium: A systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry. 2016;87:767–74.
    1. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI, et al. Clarifying confusion: The confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990;113:941–8.
    1. Breitbart W, Rosenfeld B, Roth A, Smith MJ, Cohen K, Passik S, et al. The memorial delirium assessment scale. J Pain Symptom Manage. 1997;13:128–37.
    1. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11–9.
    1. New Delhi: ICMR; 2006. ICMR Ethical guidelines for biomedical research on human participants. Central Ethics Committee on Human Research.
    1. Kim JY, Jung IK, Han C, Cho SH, Kim L, Kim SH, et al. Antipsychotics and dopamine transporter gene polymorphisms in delirium patients. Psychiatry Clin Neurosci. 2005;59:183–8.
    1. Sasaki Y, Matsuyama T, Inoue S, Sunami T, Inoue T, Denda K, et al. Aprospective, open-label, flexible-dose study of quetiapine in the treatment of delirium. J Clin Psychiatry. 2003;64:1316–21.
    1. Mittal D, Jimerson NA, Neely EP, Johnson WD, Kennedy RE, Torres RA, et al. Risperidone in the treatment of delirium: Results from a prospective open-label trial. J Clin Psychiatry. 2004;65:662–7.
    1. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry. 2000;57:249–58.
    1. Nakamura J, Uchimura N, Yamada S, Nakazawa Y, Hashizume Y, Nagamori K, et al. The effect of mianserin hydrochloride on delirium. Hum Psychopharmacol. 1995;10:289–97.
    1. Akechi T, Uchitomi Y, Okamura H, Fukue M, Kagaya A, Nishida A, et al. Usage of haloperidol for delirium in cancer patients. Support Care Cancer. 1996;4:390–2.
    1. Risch SC. Pathophysiology of schizophrenia and the role of newer antipsychotics. Pharmacotherapy. 1996;16:11–4.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir